Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Download your copy of the new events calendar and see all the online workshops, conferences, RAC exams and European online workshops RAPS has planned for 2021 at a glance.
Registration is now open for RAPS Euro Convergence 2021! Attend to join peers from EU and around the world to gain insights and exchange ideas on the regions most pressing issues.
An invaluable resource for any professional engaged in designing, composing, compiling, or commenting on regulatory documentation
From self-assessments to help you identify your strengths and areas to focus on to reference books and online courses that will help you fill in the gaps in your regulatory knowledge, RAPS has the resources to help you prepare for the RAC exam.
Posted 13 February 2018 | By Michael Mezher
In the first-ever study using the US Food and Drug Administration's (FDA) Sentinel system by non-FDA stakeholders, a team of academic and industry researchers found that a 2010 label change for proton pump inhibitors (PPIs) led to less long-term use of the drugs.
The study is also the second to be conducted using Sentinel to evaluate the impact of an FDA-mandated label change after a study by FDA officials and other researchers published in 2016 found that the use of long-acting β2-agonists (LABA) decreased after FDA added new warnings to the drugs' labels.
Sentinel was initially developed as a tool for active postmarket safety surveillance for FDA as required by Congress under the 2007 Food and Drug Administration Amendments Act (FDAAA). In the decade since its launch, FDA has expanded Sentinel to include new tools and access to data for more than 223 million US patients.
As a means of providing third party researchers in academia, industry and other government agencies with access to the bulk of Sentinel's resources, the Innovation in Medical Evidence Development and Surveillance (IMEDS) was formed in collaboration with the non-profit Reagan-Udall Foundation.
In May 2010, FDA issued a class-wide label change for PPIs due to a potential increased risk of hip and other fractures with prolonged use of the drugs reported in several observational studies and meta-analyses.
However, according to the authors of the study, it is often difficult to determine the impact label changes have on prescriber and patient behavior.
"The impact of label changes on physician and patient behavior is understudied with few examples, and when assessments are done, as with US [risk evaluation and mitigation strategies] REMS, many are not publicly disclosed or of sufficient scientific interest or rigor to be publishable," they wrote.
The authors also said that healthcare databases, such as those available through Sentinel are "underused" compared to cross-sectional patient and prescriber surveys.
Using Sentinel, the authors were able to identify nearly 1.5 million patients that took PPIs in the three years before the label change and nearly 2.25 million patients that took the drugs in the five years after.
Among those patients, the authors found that the proportion taking PPIs for longer than a year decreased from 8.4% to 7.5% and that the number of days patients were supplied PPIs fell from 130.4 days to 113.7 days in the period following the label change.
While the authors found a decrease in osteoporosis screening and interventions following the label change, they found the proportion of patients that had fractures decreased from 4.4% to 3.1% across the two periods.
"Taken at a population level, our results overall are at least suggestive that label changes and communication tools to alter certain prescriber behaviors as measured by dispensing patterns," the authors wrote, noting that their finding is consistent with FDA's finding in its study of label changes for LABAs.
Pharmacoepidemiology & Drug Safety
Regulatory Focus newsletters
All the biggest regulatory news and happenings.